Surface Oncology, Inc.
https://www.surfaceoncology.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Surface Oncology, Inc.
Compugen Still Confident Of Its TIGIT Strategy Despite Roche’s Setbacks
The small-cap biotech is not currently favored by investors but CEO Anat Cohen-Dayag tells Scrip she believes Compugen could have the optimal TIGIT strategy.
Nkarta Unveils Early But Promising Data For CAR-NK Therapies In AML, NHL
NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.
China’s Insatiable Appetite For Latest Therapies Prompts Ex-Exec To Take New Journey
After immuno-oncology, cell therapies such as CAR-Ts have attracted millions of dollars of funding in China and one former executive is now sailing into the largely uncharted waters of natural killer cells.
GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone
GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule